GLP-1 Medications May Reduce Depression and Anxiety: What the New Research Shows

If you've been taking a GLP-1 medication like semaglutide or liraglutide, you may have noticed something beyond the physical changes. Maybe the constant background hum of worry has quieted a little. Maybe you're sleeping better, or the heaviness that used to settle over your mornings has started to lift. You might have wondered whether the medication had anything to do with it — or whether you were imagining things.

You weren't imagining things. A landmark study published in The Lancet Psychiatry in 2026, drawing on Swedish national health registers covering nearly 100,000 individuals, found that GLP-1 receptor agonist use was associated with significantly lower rates of depression, anxiety, and other psychiatric conditions. The findings were so strong they surprised even the research team.

Here's what the study found, what it might mean for your mental health, and what questions remain.

What the Lancet Psychiatry Study Actually Found

Researchers analyzed data from Swedish national health registers spanning 2009 to 2022, following more than 100,000 individuals — over 20,000 of whom were prescribed GLP-1 receptor agonists such as semaglutide and liraglutide. By comparing periods when the same individuals were on versus off GLP-1 treatment, the study was able to control for many of the personal factors that make psychiatric research so difficult.

The results were striking. During periods of active GLP-1 treatment:

• Depression risk was 44% lower compared to periods when the same individuals were not taking the medication
• Anxiety disorders were reduced by 38%
• Psychiatric hospital visits dropped by 42%
• Substance use disorders were 47% lower — a finding with particular relevance for people navigating addictive behaviors alongside weight management

These are not small numbers. And because the study used a within-individual design — comparing each person to themselves during different treatment periods — it sidesteps many of the weaknesses that plague observational research.

Why GLP-1 Medications Might Affect Your Mood

The connection between a medication designed for blood sugar and weight management and improvements in depression and anxiety might seem surprising. But there are several plausible pathways, and they likely work together.

The body image and confidence pathway. Significant weight loss can change how you feel about yourself and how you move through the world. For many people, carrying excess weight is tangled up with social withdrawal and low self-worth — feelings that overlap heavily with clinical depression. When the weight begins to shift, some of that emotional burden lifts too.

The metabolic pathway. Better glycemic control has well-documented links to mood stability. Chronic inflammation, insulin resistance, and blood sugar volatility all contribute to depressive symptoms. By improving metabolic health, these medications may be addressing some of the biological underpinnings of mood disorders.

The neurobiological pathway. This is where things get especially interesting. GLP-1 receptors are found throughout the brain, including in areas that regulate mood, reward, and emotional processing. The medication isn't just working in your gut and pancreas — it's crossing the blood-brain barrier and interacting with neural circuits involved in how you experience pleasure, motivation, and anxiety. Some researchers believe this direct brain activity may explain the reduction in substance use disorders as well.

If you've been curious about how GLP-1 medications interact with your emotional landscape more broadly, our guide on mood changes and anxiety during GLP-1 treatment covers the full range of experiences people report.

What This Means If You're Experiencing Mental Health Benefits

If you've noticed your mood improving since starting a GLP-1 medication, this research offers validation. You're not making it up, and you're not alone. Tens of thousands of people in this study showed the same pattern.

That said, a few nuances matter:

Correlation within individuals is still not proof of causation. The within-person design is strong, but it's possible that other life changes coinciding with starting medication contribute to the mental health benefits. The researchers called for randomized controlled trials to confirm the findings.

The benefits appeared to be present during active treatment. This raises the question of whether the mental health improvements persist if you stop taking the medication.

Not everyone experiences mood improvement. Some people report increased anxiety, emotional flatness, or mood changes they find difficult during GLP-1 treatment. If your mood has worsened since starting treatment, that's worth discussing with your prescriber.

The Food Noise Connection

One of the most commonly reported experiences with GLP-1 medications is a quieting of what many people call "food noise" — the persistent, intrusive thoughts about food that can dominate your mental bandwidth. While the Lancet study didn't measure food noise directly, the reduction in anxiety and the improvement in overall psychiatric wellbeing may be related.

When you're no longer spending significant mental energy managing cravings, planning your next meal, or feeling conflicted about what you just ate, that cognitive and emotional space opens up. For some people, this feels like a fog lifting.

If you're curious about where you fall on the food noise spectrum, our food noise assessment tool can help you understand your current experience. And for a deeper look at what food noise actually is and how to work with it during treatment, this guide on navigating food noise is a good starting point.

What Researchers Still Want to Know

Which mechanism dominates? Is the mood improvement primarily driven by weight loss, metabolic changes, or direct brain effects? Disentangling these pathways will require carefully designed trials.

Do the benefits persist long-term? The study observed benefits during active treatment periods, but the long-term trajectory — especially after discontinuation — remains unclear.

Could GLP-1 medications eventually be prescribed for psychiatric conditions? If randomized trials confirm the findings, there may be a future where GLP-1 receptor agonists are part of the treatment toolkit for depression or anxiety.

What about the 47% reduction in substance use disorders? Early-stage clinical trials are already underway exploring GLP-1 medications for alcohol use disorder, and the Swedish data adds weight to the hypothesis that these drugs modulate reward circuitry in meaningful ways.

Putting This in Perspective

If you started a GLP-1 medication hoping to feel better in your body, and you've also started feeling better in your mind — that's a meaningful outcome. Mental health is health. The fact that a medication prescribed for one purpose may also support another is not a side effect. It's a benefit.

At the same time, medication is one piece of a larger picture. Sleep, movement, connection, and the daily habits that structure your life all matter. The research suggests that GLP-1 medications may create a more favorable internal environment for wellbeing — but you still get to decide what you build in that space.

What this study does, perhaps most importantly, is give language and legitimacy to something many people have been feeling but haven't been sure how to talk about. The quiet lifting. The softening of anxiety's grip. The sense that you have a little more room to breathe. It's not wishful thinking. According to the largest study of its kind, it's a measurable, significant pattern shared by tens of thousands of people.

And that's worth paying attention to.